Clinical trial NCT02801097: RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Official title: A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Malignant Solid Tumor
Metastatic Cancer
Advanced Cancer
Lead sponsor: EpicentRx, Inc.
Sponsor class: INDUSTRY
First posted: 2016-06-15
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan.

RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability of RRx-001 to restore the expression of aberrantly silenced genes, thus re-establishing pathway functions. However, resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular modulation, leading to improved penetration of standard chemotherapy.

Detailed description: This dose escalation study consists of 5 sequential dose cohorts each administered RRx-001 with irinotecan. After the first 3 subjects of each cohort complete Cycle 1, the safety will be assessed before moving to the next dose level. Subjects in the current cohort will continue treatment immediately following the completion of Cycle 1, for as long as therapy is tolerated and the RECIST v.1.1 definition of progression is not met.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined.
* Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening.
* Measurable disease per RECIST v1.1 by radiographic techniques
* Acceptable liver function, serum creatinine and hematological status
* Female subjects of childbearing potential, and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.
* Subjects with brain metastases are eligible

Exclusion Criteria:

* Concurrent anticancer therapy; however, radiotherapy is allowed
* Any history of hypersensitivity to irinotecan
* Cholangitis that required treatment or intervention within 4 weeks of study enrollment
* Bilirubin \> 2.0 mg/dL
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study
* If female, subject is pregnant and/or breastfeeding.
* UGT1A1\*28 homozygote or heterozygote
* BMI \>35

Primary outcomes:
measure: Number, frequency and type of adverse events
timeFrame: 14 Weeks
Secondary outcomes:
measure: Duration of clinical benefit rate
timeFrame: 1 year
measure: Progression-Free Survival
timeFrame: 1 year
measure: Overall Response rate
timeFrame: 1 year
measure: Overall Survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California, Davis
state: California
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey
state: New Jersey
Study officials:
affiliation: EpicentRx, Inc.
name: Bryan Oronsky, MD
role: STUDY_DIRECTOR
References: